This study is a non-drug follow up study to A3051123 for cardiac assessments after use of smoking cessation treatments.

• Conditions: icotine Addiction with the desire to quit smoking; MedDRA version: 17.1Level: PTClassification code 10053325Term: Smoking cessation therapySystem Organ Class: 10042613 - Surgical and medical procedures; Therapeutic area: Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04]

• Registration Number: EUCTR2011-005513-37-SK
• Lead Sponsor: Pfizer Inc., 235 East 42nd Street, New York, NY 10017

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-08-28
• Last Update Posted: 14 September 2015

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 8000

Inclusion Criteria

Subject eligibility should be reviewed and documented by an appropriately qualified member of the investigator’s study team before subjects are included in the study.
•Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
•Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
•Randomized to and completed study A3051123.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 7544
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 456

Exclusion Criteria

Subjects presenting with any of the following will not be included in the study:
1.Participation in study A3051123 ceased (ie, withdrew, lost to follow-up, etc.) prior to Week 24 final visit.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified